Increase in the degree of phosphorylation of circulating fibrinogen under thrombolytic therapy with urokinase.
Human fibrinogen is phosphorylated in vivo to an equal extent at two positions, one at Ser 3 located on fibrinopeptide A, the other at Ser 345 of the A alpha-chain. As has been shown previously, the degree of phosphorylation of the circulating fibrinogen pool can be determined in vitro from the ratio between the HPLC peaks formed by phosphorylated and non-phosphorylated fibrinopeptide A which has been cleaved from plasma fibrinogen by thrombin or reptilase. Plasma samples were obtained from patients with venous thrombosis undergoing fibrinolytic therapy with urokinase (n = 8). The degree of phosphorylation increased from about 35% before treatment to values between 50% and 70% within 48 hours. It remained at these high levels as long as urokinase was administered and declined slowly thereafter. This behaviour of the degree of phosphorylation of fibrinogen is explained by a model which assumes that fibrinogen is secreted in the phosphorylated form and then dephosphorylated in the circulation by an up to now unidentified phosphatase by first order kinetics. When this system is in steady state, the degree of phosphorylation is about 25% under normal conditions. If the elimination rate of fibrinogen is greatly enhanced by fibrinogenolysis the system will approach a new steady state with a higher degree of phosphorylation, the magnitude of which will depend on the new ratio of dephosphorylation and elimination.
D001775:Blood Circulation; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005340:Fibrinogen / Q000032:analysis / Q000378:metabolism*; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005344:Fibrinopeptide A / Q000032:analysis / Q000378:metabolism; D006801:Humans; D008297:Male; D010766:Phosphorylation; D011487:Protein Conformation; D013924:Thrombophlebitis / Q000097:blood / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D005344:Fibrinopeptide A; D005340:Fibrinogen; D014568:Urokinase-Type Plasminogen Activator